Compass Therapeutics, Inc.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics, Inc. headquartered in United States, North America, operates in the Biotechnology, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $41.2B in funding across 108 round(s). With a team of 51-100 employees, Compass Therapeutics, Inc. is actively contributing to advancements in Biotechnology. Their latest funding round, Debt Financing - Compass Therapeutics, Inc., raised $575.0K. Discover more about their projects, partnerships, and impact on our platform.